Table of Content

1 INTRODUCTION (Page No. - 36)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION
           1.3.2 MOLECULAR DIAGNOSTICS INDUSTRY: GEOGRAPHICAL SEGMENTATION
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 MARKET LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
2 RESEARCH METHODOLOGY (Page No. - 42)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Company presentations and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS 
    2.6 STUDY ASSUMPTIONS 
    2.7 RESEARCH LIMITATIONS 
    2.8 GROWTH RATE ASSUMPTIONS 
    2.9 RISK ASSESSMENT 
           2.9.1 RISK ASSESSMENT OF MARKET
    2.10 IMPACT OF ECONOMIC RECESSION ON MARKET 
3 EXECUTIVE SUMMARY (Page No. - 57)
    FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2023 VS. 2028 (USD MILLION)
    FIGURE 9 MOLECULAR DIAGNOSTICS INDUSTRY, BY TEST TYPE,  2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY SAMPLE TYPE,  2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY TECHNOLOGY,  2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY APPLICATION,  2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY END USER,  2023 VS. 2028 (USD MILLION)
    FIGURE 14 MOLECULAR DIAGNOSTICS INDUSTRY, BY REGION,  2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 63)
    4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET
    4.2 MOLECULAR DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2023 VS. 2028 
          FIGURE 16 REAGENTS & KITS TO DOMINATE MARKET IN 2028
    4.3 MARKET, BY TEST TYPE,  2023 VS. 2028 
          FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028
    4.4 MARKET, BY SAMPLE TYPE,  2023 VS. 2028 
          FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
    4.5 MARKET, BY TECHNOLOGY,  2023 VS. 2028 
          FIGURE 19 PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.6 MARKET, BY APPLICATION,  2023 VS. 2028 
          FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
    4.7 MARKET, BY END USER,  2023 VS. 2028 
          FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.8 MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 
          FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING STUDY PERIOD
5 MARKET OVERVIEW (Page No. - 68)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 23 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of infectious diseases and cancer globally
                                TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER,  2020 VS. 2025
                                TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
                    5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies
                    5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries
                    5.2.1.4 Rising technological advancements in molecular diagnostics in recent years
                    5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
                    5.2.2.2 High cost of molecular diagnostic instruments
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing significance of companion diagnostics in drug development process
                    5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union
                    5.2.4.2 Operational barriers and shortage of skills across major markets
                    5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
    5.3 PRICING ANALYSIS 
           5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER
                    TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS
    5.4 PATENT ANALYSIS 
          FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022)
           5.4.1 LIST OF MAJOR PATENTS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS INDUSTRY: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 26 MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM/MARKET MAP ANALYSIS 
          FIGURE 27 MARKET: ECOSYSTEM/MARKET MAP ANALYSIS
           5.7.1 MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT FROM NEW ENTRANTS
           5.8.2 THREAT FROM SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 REGULATORY ANALYSIS 
          TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                    5.9.1.2 Canada
           5.9.2 EUROPE
                    TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                    5.9.3.2 Japan
                                TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.3.3 India
           5.9.4 LATIN AMERICA
                    5.9.4.1 Brazil
                    5.9.4.2 Mexico
           5.9.5 MIDDLE EAST
           5.9.6 AFRICA
    5.10 TRADE ANALYSIS 
           5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
                    5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million)
    5.11 TECHNOLOGY ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 
           TABLE 11 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024
    5.13 PESTLE ANALYSIS 
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           5.14.1 REVENUE SHIFT IN MARKET
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS
                     TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%)
           5.15.2 BUYING CRITERIA
                     FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
                     TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
    5.16 CASE STUDY ANALYSIS 
           FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 99)
    6.1 INTRODUCTION 
          TABLE 14 MOLECULAR DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
          TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
    6.2 REAGENTS & KITS 
           6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET
                    TABLE 16 MARKET FOR REAGENTS & KITS, BY REGION,  2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
                    TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
                    TABLE 18 MARKET FOR INSTRUMENTS, BY REGION,  2021–2028 (USD MILLION)
    6.4 SERVICES & SOFTWARE 
           6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MARKET TO DRIVE GROWTH
                    TABLE 19 MARKET FOR SERVICES & SOFTWARE, BY REGION,  2021–2028 (USD MILLION)
7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 105)
    7.1 INTRODUCTION 
          TABLE 20 MOLECULAR DIAGNOSTICS INDUSTRY, BY TEST TYPE, 2021–2028 (USD MILLION)
           7.1.1 PRIMARY NOTES
                    7.1.1.1 Key industry insights
    7.2 LAB TESTS 
           7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
                    TABLE 21 MARKET FOR LAB TESTS, BY REGION,  2021–2028 (USD MILLION)
    7.3 POC TESTS 
           7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH
                    TABLE 22 MARKET FOR POC TESTS, BY REGION,  2021–2028 (USD MILLION)
8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE (Page No. - 110)
    8.1 INTRODUCTION 
          TABLE 23 MOLECULAR DIAGNOSTICS INDUSTRY, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
    8.2 BLOOD, SERUM, AND PLASMA 
           8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
                    TABLE 24 MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2028 (USD MILLION)
    8.3 URINE 
           8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
                    TABLE 25 MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
    8.4 OTHER SAMPLE TYPES 
          TABLE 26 MARKET FOR OTHER SAMPLE TYPES, BY REGION,  2021–2028 (USD MILLION)
9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 114)
    9.1 INTRODUCTION 
           9.1.1 PRIMARY NOTES
                    9.1.1.1 Key industry insights
                                TABLE 27 MOLECULAR DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    9.2 POLYMERASE CHAIN REACTION 
           9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET
                    TABLE 28 MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION)
    9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 
           9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET
                    TABLE 29 MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 
           9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
                    TABLE 30 MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
    9.5 IN SITU HYBRIDIZATION 
           9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
                    TABLE 31 MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
    9.6 DNA MICROARRAYS 
           9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
                    TABLE 32 MARKET FOR DNA MICROARRAYS, BY REGION,  2021–2028 (USD MILLION)
    9.7 OTHER TECHNOLOGIES 
          TABLE 33 MARKET FOR OTHER TECHNOLOGIES, BY REGION,  2021–2028 (USD MILLION)
10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 123)
     10.1 INTRODUCTION 
             TABLE 34 MOLECULAR DIAGNOSTICS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
     10.2 INFECTIOUS DISEASE DIAGNOSTICS 
             TABLE 35 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY REGION, 2021–2028 (USD MILLION)
             TABLE 36 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             10.2.1 HEPATITIS
                        10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment
                                      TABLE 37 HEPATITIS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 38 HEPATITIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.2 HIV
                        10.2.2.1 Increased global prevalence of HIV to propel segment
                                      TABLE 39 HIV MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 40 HIV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.3 CT/NG
                        10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally
                                      TABLE 41 CT/NG MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 42 CT/NG MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.4 HAIS
                        10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market
                                      TABLE 43 HAIS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 44 HAIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.5 HPV
                        10.2.5.1 Technological advancements for preventing HPV infections to augment market
                                      TABLE 45 HPV MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 46 HPV MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.6 TUBERCULOSIS
                        10.2.6.1 Increasing burden of TB globally to propel market
                                      TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.7 INFLUENZA
                        10.2.7.1 Rising focus on decreasing spread of influenza to propel segment
                                      TABLE 49 INFLUENZA MARKET, BY REGION, 2021–2028 (USD MILLION)
                                      TABLE 50 INFLUENZA MARKET, BY REGION, 2021–2028 (MILLION TESTS)
             10.2.8 OTHER INFECTIOUS DISEASES
                        TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.3 ONCOLOGY TESTING 
             TABLE 52 MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 53 MARKET FOR ONCOLOGY TESTING, BY REGION,  2021–2028 (USD MILLION)
             10.3.1 BREAST CANCER
                        10.3.1.1 Increasing prevalence of breast cancer among females to boost market
                                      TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                                      TABLE 55 BREAST CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
             10.3.2 COLORECTAL CANCER
                        10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market
                                      TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
             10.3.3 LUNG CANCER
                        10.3.3.1 Increasing research for lung cancer biomarkers to drive market
                                      TABLE 57 LUNG CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
             10.3.4 PROSTATE CANCER
                        10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market
                                      TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021–2028 (USD MILLION)
             10.3.5 OTHER CANCERS
                        TABLE 59 GLOBAL CANCER INCIDENCE, 2020
                        TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.4 GENETIC TESTING 
             10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET
                        TABLE 61 MARKET FOR GENETIC TESTING, BY REGION,  2021–2028 (USD MILLION)
     10.5 OTHER APPLICATIONS 
             TABLE 62 MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
     10.6 COVID-19 
             10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET
                        TABLE 63 MARKET FOR COVID-19, BY REGION,  2021–2028 (USD MILLION)
11 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 144)
     11.1 INTRODUCTION 
             TABLE 64 MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     11.2 DIAGNOSTIC LABORATORIES 
             11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
                        TABLE 65 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
     11.3 HOSPITALS & CLINICS 
             11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
                        TABLE 66 MARKET FOR HOSPITALS & CLINICS, BY REGION,  2021–2028 (USD MILLION)
     11.4 OTHER END USERS 
             TABLE 67 MARKET FOR OTHER END USERS, BY REGION,  2021–2028 (USD MILLION)
12 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 149)
     12.1 INTRODUCTION 
             TABLE 68 MOLECULAR DIAGNOSTICS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     12.2 NORTH AMERICA 
             FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
             TABLE 69 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 70 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 71 NORTH AMERICA: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
             TABLE 72 NORTH AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 73 NORTH AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 74 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 75 NORTH AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 76 NORTH AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
             12.2.2 US
                        12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
                                      TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 78 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 79 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 80 US: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 81 US: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 82 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.3 CANADA
                        12.2.3.1 High availability of funding for genomics research to fuel market
                                      TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 84 CANADA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 85 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 86 CANADA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 87 CANADA: MARKET FOR ONCOLOGY TESTING,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 88 CANADA: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER,  2021–2028 (USD MILLION)
     12.3 EUROPE 
             TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 90 EUROPE: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 91 EUROPE: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
             TABLE 92 EUROPE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 93 EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 94 EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 95 EUROPE: MARKET FOR ONCOLOGY TESTING,  BY TYPE, 2021–2028 (USD MILLION)
             TABLE 96 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
             12.3.2 GERMANY
                        12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market
                                      TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 98 GERMANY: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 99 GERMANY: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 100 GERMANY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 101 GERMANY: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 102 GERMANY: MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.3.3 UK
                        12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market
                                      TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 104 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 105 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 106 UK: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 107 UK: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 108 UK: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             12.3.4 FRANCE
                        12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
                                      TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 110 FRANCE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 111 FRANCE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 112 FRANCE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 113 FRANCE: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 114 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.5 ITALY
                        12.3.5.1 Adoption of advanced diagnostic technologies to support market
                                      TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 116 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 117 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 118 ITALY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 119 ITALY: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 120 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.6 SPAIN
                        12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
                                      TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 122 SPAIN: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 123 SPAIN: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 124 SPAIN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 125 SPAIN: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             12.3.7 RUSSIA
                        12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market
                                      TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 128 RUSSIA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 129 RUSSIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 130 RUSSIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 131 RUSSIA: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 132 RUSSIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.8 REST OF EUROPE
                        TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 134 REST OF EUROPE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 135 REST OF EUROPE: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 136 REST OF EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 137 REST OF EUROPE: MARKET FOR ONCOLOGY TESTING,  BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 138 REST OF EUROPE: MARKET, BY END USER,  2021–2028 (USD MILLION)
     12.4 ASIA PACIFIC 
             FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
             TABLE 139 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 140 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 141 ASIA PACIFIC: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
             TABLE 142 ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 143 ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 144 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 145 ASIA PACIFIC: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 146 ASIA PACIFIC: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER,  2021–2028 (USD MILLION)
             12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
             12.4.2 CHINA
                        12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market
                                      TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 148 CHINA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 149 CHINA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 150 CHINA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 151 CHINA: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 152 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.3 JAPAN
                        12.4.3.1 Universal healthcare reimbursement policy to support market
                                      TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 154 JAPAN: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 155 JAPAN: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 156 JAPAN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 157 JAPAN: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 158 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.4 INDIA
                        12.4.4.1 Increased private & public investments and large patient population to drive market
                                      TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 160 INDIA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 161 INDIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 162 INDIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 163 INDIA: MARKET FOR ONCOLOGY TESTING, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 164 INDIA: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             12.4.5 AUSTRALIA
                        12.4.5.1 High prevalence of infectious diseases to fuel market
                                      TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 166 AUSTRALIA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 167 AUSTRALIA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 168 AUSTRALIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 169 AUSTRALIA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 170 AUSTRALIA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.4.6 REST OF ASIA PACIFIC
                        TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 172 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 173 REST OF ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 174 REST OF ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 175 REST OF ASIA PACIFIC: MARKET FOR ONCOLOGY TESTING,  BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 176 REST OF ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
     12.5 LATIN AMERICA 
             TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 178 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 179 LATIN AMERICA: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
             TABLE 180 LATIN AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 181 LATIN AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
             TABLE 182 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 183 LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 184 LATIN AMERICA: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER,  2021–2028 (USD MILLION)
             12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA
             12.5.2 BRAZIL
                        12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
                                      TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 186 BRAZIL: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 187 BRAZIL: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 188 BRAZIL: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 189 BRAZIL: MARKET FOR ONCOLOGY TESTING,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 190 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.3 MEXICO
                        12.5.3.1 Improving accessibility and affordability of healthcare services to aid market
                                      TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 192 MEXICO: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 193 MEXICO: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 194 MEXICO: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 195 MEXICO: MARKET FOR ONCOLOGY TESTING,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 196 MEXICO: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.4 REST OF LATIN AMERICA
                        TABLE 197 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 198 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 199 REST OF LATIN AMERICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 200 REST OF LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 201 REST OF LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 202 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS INDUSTRY, BY END USER,  2021–2028 (USD MILLION)
     12.6 MIDDLE EAST & AFRICA 
             12.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
                        TABLE 203 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT &  SERVICE, 2021–2028 (USD MILLION)
                        TABLE 204 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE TYPE,  2021–2028 (USD MILLION)
                        TABLE 205 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 206 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 207 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 208 MIDDLE EAST & AFRICA: MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 209 MIDDLE EAST & AFRICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.6.2 IMPACT OF ECONOMIC RECESSION ON MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE (Page No. - 227)
     13.1 OVERVIEW 
     13.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
                        TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
     13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 33 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR DIAGNOSTICS INDUSTRY
     13.4 MARKET SHARE ANALYSIS 
             FIGURE 34 MARKET SHARE, BY KEY PLAYER (2022)
             TABLE 211 MARKET: DEGREE OF COMPETITION
             13.4.1 MARKET SHARE AND RANKING ANALYSIS, BY TECHNOLOGY
                        13.4.1.1 Polymerase chain reaction (PCR)
                                      FIGURE 35 GLOBAL MARKET SHARE FOR PCR, BY KEY PLAYER (2022)
                        13.4.1.2 DNA sequencing and NGS
                                      FIGURE 36 GLOBAL MARKET SHARE FOR DNA SEQUENCING & NGS, BY KEY PLAYER (2022)
                        13.4.1.3 Isothermal nucleic acid amplification technology (INAAT)
                                      TABLE 212 GLOBAL MARKET RANKING FOR INAAT, BY KEY PLAYER, 2022
                        13.4.1.4 In situ hybridization (ISH)
                                      TABLE 213 GLOBAL MARKET RANKING FOR ISH, BY KEY PLAYER, 2022
             13.4.2 MARKET RANKING ANALYSIS,  BY APPLICATION
                        13.4.2.1 Infectious diseases
                                       TABLE 214 GLOBAL MARKET RANKING FOR INFECTIOUS DISEASES,  BY KEY PLAYER, 2022
     13.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 
             13.5.1 LIST OF EVALUATED VENDORS
             13.5.2 STARS
             13.5.3 EMERGING LEADERS
             13.5.4 PERVASIVE PLAYERS
             13.5.5 PARTICIPANTS
                        FIGURE 37 MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
     13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 
             13.6.1 PROGRESSIVE COMPANIES
             13.6.2 STARTING BLOCKS
             13.6.3 RESPONSIVE COMPANIES
             13.6.4 DYNAMIC COMPANIES
                        FIGURE 38 MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
     13.7 COMPETITIVE BENCHMARKING 
             13.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS
                        FIGURE 39 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS INDUSTRY
                        TABLE 215 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
                        TABLE 216 COMPANY PRODUCT & SERVICE FOOTPRINT
                        TABLE 217 COMPANY REGIONAL FOOTPRINT
                        TABLE 218 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
     13.8 COMPETITIVE SCENARIO 
             13.8.1 KEY PRODUCT LAUNCHES
                        TABLE 219 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
             13.8.2 KEY DEALS
                        TABLE 220 KEY DEALS
14 COMPANY PROFILES (Page No. - 243)
     14.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             14.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 221 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             14.1.2 HOLOGIC, INC.
                        TABLE 222 HOLOGIC, INC.: COMPANY OVERVIEW
                        FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
             14.1.3 ABBOTT LABORATORIES
                        TABLE 223 ABBOTT LABORATORIES: COMPANY OVERVIEW
                        FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             14.1.4 BIOMÉRIEUX
                        TABLE 224 BIOMÉRIEUX: COMPANY OVERVIEW
                        FIGURE 43 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
             14.1.5 THERMO FISHER SCIENTIFIC INC.
                        TABLE 225 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             14.1.6 QIAGEN
                        TABLE 226 QIAGEN: COMPANY OVERVIEW
                        FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2022)
             14.1.7 PERKINELMER INC.
                        TABLE 227 PERKINELMER INC.: COMPANY OVERVIEW
                        FIGURE 46 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
             14.1.8 MYRIAD GENETICS, INC.
                        TABLE 228 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
                        FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
             14.1.9 SIEMENS HEALTHINEERS AG
                        TABLE 229 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
                        FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
             14.1.10 DANAHER
                        TABLE 230 DANAHER: COMPANY OVERVIEW
                        FIGURE 49 DANAHER: COMPANY SNAPSHOT (2022)
     14.2 OTHER PLAYERS 
             14.2.1 ILLUMINA, INC.
             14.2.2 BECTON, DICKINSON AND COMPANY
             14.2.3 GRIFOLS, S.A.
             14.2.4 QUIDELORTHO CORPORATION
             14.2.5 AGILENT TECHNOLOGIES, INC.
             14.2.6 DIASORIN S.P.A.
             14.2.7 EXACT SCIENCES CORPORATION
             14.2.8 GENETIC SIGNATURES
             14.2.9 MDXHEALTH
             14.2.10 HTG MOLECULAR DIAGNOSTICS, INC.
             14.2.11 BIOCARTIS
             14.2.12 TBG DIAGNOSTICS LIMITED
                        TABLE 231 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
             14.2.13 VELA DIAGNOSTICS
                        TABLE 232 VELA DIAGNOSTICS: COMPANY OVERVIEW
             14.2.14 AMOY DIAGNOSTICS CO., LTD.
                        TABLE 233 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
             14.2.15 ELITECHGROUP
                        TABLE 234 ELITECHGROUP: COMPANY OVERVIEW
             14.2.16 MOLBIO DIAGNOSTICS PVT. LTD.
                        TABLE 235 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
             14.2.17 SAVYON DIAGNOSTICS
                        TABLE 236 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
             14.2.18 ABACUS DIAGNOSTICA OY
                        TABLE 237 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
             14.2.19 GENEOMBIO TECHNOLOGIES PVT. LTD.
                        TABLE 238 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX (Page No. - 311)
     15.1 DISCUSSION GUIDE 
     15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     15.3 CUSTOMIZATION OPTIONS 
     15.4 RELATED REPORTS 
     15.5 AUTHOR DETAILS

12.6 MIDDLE EAST & AFRICA 222
12.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET 222
TABLE 203 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 223
TABLE 204 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 223
TABLE 205 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 224
TABLE 206 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 224
TABLE 207 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 208 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 209 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 226
12.6.2 IMPACT OF ECONOMIC RECESSION ON MIDDLE EAST & AFRICA 226
13 COMPETITIVE LANDSCAPE 227
13.1 OVERVIEW 227
13.2 STRATEGIES ADOPTED BY KEY PLAYERS 227
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET 228
TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES 228
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 230
FIGURE 33 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR DIAGNOSTICS MARKET 230
13.4 MARKET SHARE ANALYSIS 231
FIGURE 34 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022) 231
TABLE 211 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION 231
13.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE AND RANKING ANALYSIS, BY TECHNOLOGY 233
13.4.1.1 Polymerase chain reaction (PCR) 233
FIGURE 35 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE FOR PCR, BY KEY PLAYER (2022) 233
13.4.1.2 DNA sequencing and NGS 233
FIGURE 36 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE FOR DNA SEQUENCING & NGS, BY KEY PLAYER (2022) 233
13.4.1.3 Isothermal nucleic acid amplification technology (INAAT) 234
TABLE 212 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INAAT, BY KEY PLAYER, 2022 234
13.4.1.4 In situ hybridization (ISH) 234
TABLE 213 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR ISH, BY KEY PLAYER, 2022 234
13.4.2 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY APPLICATION 234
13.4.2.1 Infectious diseases 234
TABLE 214 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2022 234
13.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 235
13.5.1 LIST OF EVALUATED VENDORS 235
13.5.2 STARS 235
13.5.3 EMERGING LEADERS 235
13.5.4 PERVASIVE PLAYERS 235
13.5.5 PARTICIPANTS 235
FIGURE 37 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 236
13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 237
13.6.1 PROGRESSIVE COMPANIES 237
13.6.2 STARTING BLOCKS 237
13.6.3 RESPONSIVE COMPANIES 237
13.6.4 DYNAMIC COMPANIES 237
FIGURE 38 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 238
13.7 COMPETITIVE BENCHMARKING 239
13.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS 239
FIGURE 39 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET 239
TABLE 215 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 239
TABLE 216 COMPANY PRODUCT & SERVICE FOOTPRINT 240
TABLE 217 COMPANY REGIONAL FOOTPRINT 240
TABLE 218 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 240
?
13.8 COMPETITIVE SCENARIO 241
13.8.1 KEY PRODUCT LAUNCHES 241
TABLE 219 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 241
13.8.2 KEY DEALS 242
TABLE 220 KEY DEALS 242
14 COMPANY PROFILES 243
14.1 KEY PLAYERS 243
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 F. HOFFMANN-LA ROCHE LTD. 243
TABLE 221 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 243
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 244
14.1.2 HOLOGIC, INC. 250
TABLE 222 HOLOGIC, INC.: COMPANY OVERVIEW 250
FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 251
14.1.3 ABBOTT LABORATORIES 255
TABLE 223 ABBOTT LABORATORIES: COMPANY OVERVIEW 255
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 256
14.1.4 BIOM?RIEUX 260
TABLE 224 BIOM?RIEUX: COMPANY OVERVIEW 260
FIGURE 43 BIOM?RIEUX: COMPANY SNAPSHOT (2022) 261
14.1.5 THERMO FISHER SCIENTIFIC INC. 266
TABLE 225 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 266
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 267
14.1.6 QIAGEN 271
TABLE 226 QIAGEN: COMPANY OVERVIEW 271
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2022) 272
14.1.7 PERKINELMER INC. 276
TABLE 227 PERKINELMER INC.: COMPANY OVERVIEW 276
FIGURE 46 PERKINELMER INC.: COMPANY SNAPSHOT (2022) 277
14.1.8 MYRIAD GENETICS, INC. 279
TABLE 228 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 279
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022) 280
14.1.9 SIEMENS HEALTHINEERS AG 282
TABLE 229 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 282
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 283
14.1.10 DANAHER 285
TABLE 230 DANAHER: COMPANY OVERVIEW 285
FIGURE 49 DANAHER: COMPANY SNAPSHOT (2022) 286
?
14.2 OTHER PLAYERS 289
14.2.1 ILLUMINA, INC. 289
14.2.2 BECTON, DICKINSON AND COMPANY 290
14.2.3 GRIFOLS, S.A. 291
14.2.4 QUIDELORTHO CORPORATION 292
14.2.5 AGILENT TECHNOLOGIES, INC. 293
14.2.6 DIASORIN S.P.A. 295
14.2.7 EXACT SCIENCES CORPORATION 296
14.2.8 GENETIC SIGNATURES 297
14.2.9 MDXHEALTH 298
14.2.10 HTG MOLECULAR DIAGNOSTICS, INC. 299
14.2.11 BIOCARTIS 300
14.2.12 TBG DIAGNOSTICS LIMITED 301
TABLE 231 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW 301
14.2.13 VELA DIAGNOSTICS 302
TABLE 232 VELA DIAGNOSTICS: COMPANY OVERVIEW 302
14.2.14 AMOY DIAGNOSTICS CO., LTD. 303
TABLE 233 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 303
14.2.15 ELITECHGROUP 304
TABLE 234 ELITECHGROUP: COMPANY OVERVIEW 304
14.2.16 MOLBIO DIAGNOSTICS PVT. LTD. 306
TABLE 235 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW 306
14.2.17 SAVYON DIAGNOSTICS 308
TABLE 236 SAVYON DIAGNOSTICS: COMPANY OVERVIEW 308
14.2.18 ABACUS DIAGNOSTICA OY 309
TABLE 237 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW 309
14.2.19 GENEOMBIO TECHNOLOGIES PVT. LTD. 310
TABLE 238 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW 310
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 311
15.1 DISCUSSION GUIDE 311
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 316
15.3 CUSTOMIZATION OPTIONS 318
15.4 RELATED REPORTS 318
15.5 AUTHOR DETAILS 319